JAMA Oncology:儿童癌症史可以影响职业发展

2017-10-21 海北 MedSci原创

儿童时期不幸患有癌症,除了对身体造成不良影响外,还会影响其他方面,比如职业生涯吗?有猜测表明,由于健康保险的原因,儿童癌症的幸存者们相对更不愿意进行职业变动。

儿童时期不幸患有癌症,除了对身体造成不良影响外,还会影响其他方面,比如职业生涯吗?有猜测表明,由于健康保险的原因,儿童癌症的幸存者们相对更不愿意进行职业变动。

来自犹他大学的研究人员就此进行了探究。其从全职就业儿童癌症幸存者的既定多机构队列研究中抽取数据,研究“工作锁定”(保持工作相关的健康保险)的流行率。随机的兄弟姐妹样本被作为对照组。研究人员探讨了癌症幸存者工作锁定的相关因素。

研究人员收集的数据包括社会人口学因素,保险范围,慢性医疗条件和治疗方式,并收集了参与者自我报告的工作锁定与工作锁定相关因素。。

522名参与者中,394名是癌症幸存者(男性54.5%),128名是兄弟姐妹(51.5%男性)。癌症幸存者中,23.2%(95CI18.9-28.1%)报告了工作锁定,而兄弟姐妹中只有16.8%(95CI11.1-25.0%)(P = 0.16)。在之前有健康保险被拒经历的幸存者的工作锁定更常见(相对风险[RR], 1.60; 95% CI, 1.03-2.52)。有支付医疗费用问题的幸存者中,工作锁定也更常见(RR, 2.43; 95% CI, 1.56-3.80)。在幸存者中,女性(RR, 1.70; 95% CI, 1.11-2.59; P=0.01),具有严重,残疾或危及生命的健康状况(RR, 1.72; 95% CI, 1.09-2.69; P=0.02)等因素也与工作锁定相关联。

因此,研究人员的数据表明,工作锁定在全职受雇的儿童癌症幸存者中很常见。为了维持健康保险而决定继续工作,可能会影响职业发展轨迹,降低潜在的收入能力,最终影响到生活质量。


原始出处:

Anne C. Kirchhoff et al. “Job Lock” Among Long-term Survivors of Childhood CancerJAMA Oncology, 2017; DOI: 10.1001/jamaoncol.2017.3372


本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674426, encodeId=808416e4426fd, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 03 12:58:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776254, encodeId=04881e762545d, content=<a href='/topic/show?id=0a0a8058410' target=_blank style='color:#2F92EE;'>#职业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80584, encryptionId=0a0a8058410, topicName=职业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13238890448, createdName=cooco, createdTime=Mon Nov 27 00:58:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865155, encodeId=51c8186515537, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 28 08:58:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511117, encodeId=5da0151111ecd, content=<a href='/topic/show?id=e1372836021' target=_blank style='color:#2F92EE;'>#儿童癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28360, encryptionId=e1372836021, topicName=儿童癌症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3910291816, createdName=guozhenyu, createdTime=Mon Oct 23 05:58:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674426, encodeId=808416e4426fd, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 03 12:58:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776254, encodeId=04881e762545d, content=<a href='/topic/show?id=0a0a8058410' target=_blank style='color:#2F92EE;'>#职业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80584, encryptionId=0a0a8058410, topicName=职业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13238890448, createdName=cooco, createdTime=Mon Nov 27 00:58:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865155, encodeId=51c8186515537, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 28 08:58:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511117, encodeId=5da0151111ecd, content=<a href='/topic/show?id=e1372836021' target=_blank style='color:#2F92EE;'>#儿童癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28360, encryptionId=e1372836021, topicName=儿童癌症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3910291816, createdName=guozhenyu, createdTime=Mon Oct 23 05:58:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674426, encodeId=808416e4426fd, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 03 12:58:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776254, encodeId=04881e762545d, content=<a href='/topic/show?id=0a0a8058410' target=_blank style='color:#2F92EE;'>#职业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80584, encryptionId=0a0a8058410, topicName=职业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13238890448, createdName=cooco, createdTime=Mon Nov 27 00:58:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865155, encodeId=51c8186515537, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 28 08:58:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511117, encodeId=5da0151111ecd, content=<a href='/topic/show?id=e1372836021' target=_blank style='color:#2F92EE;'>#儿童癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28360, encryptionId=e1372836021, topicName=儿童癌症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3910291816, createdName=guozhenyu, createdTime=Mon Oct 23 05:58:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-09-28 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674426, encodeId=808416e4426fd, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 03 12:58:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776254, encodeId=04881e762545d, content=<a href='/topic/show?id=0a0a8058410' target=_blank style='color:#2F92EE;'>#职业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80584, encryptionId=0a0a8058410, topicName=职业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d13238890448, createdName=cooco, createdTime=Mon Nov 27 00:58:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865155, encodeId=51c8186515537, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 28 08:58:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511117, encodeId=5da0151111ecd, content=<a href='/topic/show?id=e1372836021' target=_blank style='color:#2F92EE;'>#儿童癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28360, encryptionId=e1372836021, topicName=儿童癌症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a3910291816, createdName=guozhenyu, createdTime=Mon Oct 23 05:58:00 CST 2017, time=2017-10-23, status=1, ipAttribution=)]

相关资讯

Nature:促进肿瘤生长的机制:循环乳酸盐

肿瘤从他们所在的患者身体获得能量和生长生存所必需的营养。虽然这些营养素主要由循环血液供应,但我们对这些营养物质的了解以及肿瘤的使用方式是不完整的。识别肿瘤营养物质及其使用方法可能揭示了癌症治疗的新方法。新泽西州罗茨格癌症研究所和普林斯顿大学研究人员的研究令人惊奇地发现,循环乳酸而不是葡萄糖是肿瘤和大多数正常组织的代谢燃料来源。循环乳酸盐用于产生能量,释放葡萄糖以支持对肿瘤生长重要的代谢功能。

Mol Cell:从主要癌症基因中找到突破口

一项新的研究证明了更好的理解癌症基因的关键。来自巴伯汉姆研究所的研究人员与阿斯利康生物技术研究所的研究人员们共同合作,深入了解PTEN基因,它的功能在于控制细胞生长和行为,如果其损失,就会导致某些癌症的发展。

Nat Commun:慢性炎症何以导致癌变?

【突变基因被发现引发炎症的癌变效应】称为p53的人类基因,通常被称为“基因组的监护人”,是众所周知的,以抵抗肿瘤的形成和进展。然而,p53的突变形式与任何其他基因的更多的人类癌症病例相关联。调查癌细胞如何对人体周围环境作出反应的核心机制,加利福尼亚大学圣地亚哥分校生物学家发现了有关突变型p53的新证据,可能会重塑我们对肿瘤生长的理解,最终将有助于治疗癌症。在加州大学圣地亚哥分校生物科学系Shann

美疾控中心:美国40%癌症病例与超重肥胖有关!

美国疾病控制和预防中心日前发布报告说,美国目前40%的癌症病例与体重超重和肥胖相关,超重和肥胖问题正在威胁美国过去20年取得的抗癌进展。

PNAS:新研究增加细胞对辐射的抵抗力,打开了癌症治愈大门

约翰霍普金斯大学的生物学家,已经展示了一种方法来增加细胞对辐射的抵抗力,这可能有助于改善癌症治疗。

88岁医学泰斗汤钊猷出新作:治疗癌症要“消灭与改造并举”

“癌症不是绝症,癌症病人也可以活到百岁。”10月18日晚,中国工程院院士汤钊猷在签名赠书仪式上说。当晚,汤钊猷签名赠书仪式在上海白玉兰剧场举行。活动现场,中国工程院院士、医学泰斗汤钊猷教授向上海市癌症康复俱乐部的会员,签名赠送最新力作《控癌战,而非抗癌战——〈论持久战〉与癌症防控方略》。此书系汤钊猷抗癌三部曲系列着作之一,将于2018年初正式出版。此次活动由上海方心健康科技发展股份有限公司、上海东